Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
M-
If sbody interested: votes published
z-
i-
l-
s-
Nope, but:
(i) I expect the result later than July 5
(ii) That could be (more likely) a hedge
Best,
G
s-
FYI: I am in.
Best,
G
N-
s-
- As the current business: $ 5.00 - 9-99 in 2024
- no dividend
- acquire new product ... that could affect the pps
Best,
G
N-
N-
R-
c-
l-
N-
Yes.
(i) I do not see any "strong" direction"
(ii) Do not expect any* significant news till 10-Q2 (* meanwhile China news could come any day)
(iii) Meanwhile I expect that Q2 will be 20+% better than Q1 as Revenue / Gross Margin, CF could be +/- 0 (or net positive) Q2 2021 was the strongest q in 2021 the Q2 22 will be app. -20% vs Q2 2021 ... I feel the market will not appreciate it.
+ CFRX will release interim, futility analysis in July (more likely at beginning) so I would like to generate more powder for reentry
Best,
G
i-
i-
I am just curious: Do you still have EVFM?
Best,
G
ps.: sorry if it is painful question
r-
R-
They are selling in EUR in the "EU".
EUR/USD: 1.10 -> 160 EUR = 176 USD
EUR/USD: 1.05 -> 160 EUR = 168 USD
EUR/USD: 1.00 -> 160 EUR = 160 USD
Stronger USD is less revenue - in USD - from the EUR zone.
Best,
G
R-
M-
It was somebody else ... I am "pro" combo ... I do not remember / could not find anything else about combo by me other than Monday, May 30, 2022 4:25:18 PM
Best,
G
l-
L-
z-
N-
N-
l-
s-
r-
s-
The recent, significant increase is a little bit suspicious* for me ... I saw the same in several case - immediately - before dilution.
* I think it was a little bit too early ... and too big for July news.
Best,
G
K-
N-
With a little cooperation you could get everything from PACER free of charge ... as the first $15 / quarter / user will not billed.
Enough user and well organized ... and it is done.
Best,
G
z-
z-
o-
I am out ... now.
N-
Nope. It is a DS in Hungary .. app. $ 16 / 28 capsules (1 bottle).
Best,
G
B-
I KNOW that statement re: inventories (by Kiwi) is incorrect, misleading.
Best,
G
o-
AG ...
(i) it will get "automatically" generic tier ... less co-pay
(ii) 100% is the same as V ... same COGS, process, etc. the only difference that it is w/o name (Vascepa) ... but could be branded (e.g. Vazkepa)
(iii) meanwhile it will take market share from V it does not matter ... does not decrease overall revenue ... MEANWHILE will take market share from gV ... overall market share will be higher
Best,
G